4-(heptyloxy)-N-methylbenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(heptyloxy)-N-methylbenzamide
• 英文别名: 4-heptoxy-N-methylbenzamide
• 化学式: C₁₅H₂₃NO₂
• 分子量: 249.353
• InChiKey: AJQDPVXTIQDCKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  甲醇 、 4-(庚氧基)苯甲酰胺 在 C₅₄H₄₃ClN₃P₂Ru⁽¹⁺⁾*F₆P^(1-) 、 caesium carbonate 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以87%的产率得到4-(heptyloxy)-N-methylbenzamide
  参考文献：
  名称：

  甲醇催化钌催化合成N-甲基化酰胺

  摘要：

  实现了在钌（II）催化剂存在下使用甲醇有效合成N-甲基化酰胺的方法。值得注意的是，应用该方法，实现了串联C-甲基化和N-甲基化以合成α-甲基N-甲基化酰胺。此外，进行了一些动力学研究和使用合理的中间体进行的对照实验，以了解这一新颖的方案。此外，进行了详细的计算研究以了解这种转变的机理。

  DOI：

  10.1021/acs.orglett.9b01925

文献信息

• PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF
  申请人：MORITA Kohei

  公开号：US20130131134A1

  公开（公告）日：2013-05-23

  A compound represented by the following general formula (1) or a salt thereof, which has superior inhibitory activity against type 4 PLA 2 , and thus has prostaglandin and/or leucotriene production suppressing action [X represents a halogen atom, an alkyl group which may be substituted, or the like, Y represents hydrogen atom or an alkyl group which may be substituted, and Z represents hydrogen atom or an alkyl group which may be substituted].

  以下为通式（1）所表示的化合物或其盐，具有优异的对4型磷脂酶A2的抑制活性，因此具有前列腺素和/或白三烯的产生抑制作用 [其中，X代表卤素原子，可被取代的烷基或类似物，Y代表氢原子或可被取代的烷基，Z代表氢原子或可被取代的烷基]。
• GLP-1 receptor modulators
  申请人：Celgene International II SÀRL

  公开号：US10259823B2

  公开（公告）日：2019-04-16

  Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

  本研究提供了调节胰高血糖素样肽 1（GLP-1）受体的化合物及其合成方法，以及治疗和/或预防使用方法。此类化合物可单独作为 GLP-1 受体的调节剂或增效剂，或与 GLP-1(7-36) 和 GLP-1(9-36)等增量肽一起使用，或与艾塞那肽和利拉鲁肽等肽类疗法一起使用，并具有以下一般结构（其中""代表化合物的 R 和 S 形式中的一种或两种）： 其中 A、B、C、Y1、Y2、Z、R1、R2、R3、R4、R5、W1、n、p 和 q 如本文所定义。
• Composition, retardation plate, and liquid-crystal display device
  申请人：Li Yi

  公开号：US20080090027A1

  公开（公告）日：2008-04-17

  A composition comprising at least one liquid-crystal compound and a polymer having at least one group of the following formula (A) as the constitutive unit thereof: wherein Mp represents a trivalent linking group; L represents a single bond, or a bivalent linking group; X represents a substituted or unsubstituted functional group having a cyclic structure.
• LIQUID CRYSTAL COMPOSITION, RETARDATION PLATE, LIQUID CRYSTAL DISPLAY DEVICE, AND PROCESS FOR PRODUCING RETARDATION PLATE
  申请人：LI Yi

  公开号：US20100078592A1

  公开（公告）日：2010-04-01

  A composition comprising at least one liquid crystal compound, and at least one polymer is disclosed. The polymer comprises a constitutional unit represented by a following formula (A) and a constitutional unit derived from a monomer having a fluoroaliphatic group(s): wherein Mp represents a trivalent group constituting fully or partially a polymer main chain; L represents a single bond or a divalent linking group; and X represents a substituted or non-substituted aromatic condensed ring group.
• NOVEL GLP-1 RECEPTOR MODULATORS
  申请人：Celgene International II SÀRL

  公开号：US20170313717A1

  公开（公告）日：2017-11-02

  Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ ” represents either or both the R and S form of the compound): where A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.